Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients

American Journal of Nephrology

Volumn 16, Issue 4, 1996, Pages 304-308

  Allegra, Vincenzo ^a   Mengozzi, Giacomo ^a   Martimbianco, Lucia ^a   Vasile, Alfonso ^a  

^a Ospedale di Palmanova   (Italy)

Author keywords

Erythropoietin; Glucose metabolism; Hemodialysis; Insulin resistance

Indexed keywords

ANTIANEMIC AGENT; C PEPTIDE; ERYTHROPOIETIN; GLUCOSE; HEMOGLOBIN; IMMUNOREACTIVE INSULIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL;

ADULT; AGED; C-PEPTIDE; ERYTHROPOIETIN; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; TIME FACTORS;

EID: 0030012793     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169014     Document Type: Article

References (33)

1. Scigalla P, Wicczorek L, Bicker U: Treatment of renal anemia with recombinant human erythropoietin: European experience; in Gar-nick MB (ed): Erythropoietin in Clinical Applications: An International Perspective. New York. Dekker. 1990. pp 141-182.
2. Sobota JT: Erythropoietin treatment of end-stage renal disease: North American and Japanese experience; in Gamick MB (ed): Erythropoietin in Clinical Applications: An International Perspective. New York, Dekker, 1990, pp 183-219.
3. Winearls CG, Oliver DO, Pippard MJ, et al: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;ii:1175-1178.
4. Eschbach JW, Egric JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase 1 and II clinical trial. N Engl J Med 1987;316:73-78.
5. Fischer CH, Scigalla P, Park W, et al: Influence of rHuEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency; in Baldamus CA. Koch KM, Scigalla P. Wieczorek L (eds): Erythropoietin: From Molecular Structure to Clinical Application. Contrib Nephrol. Basel, Karger, 1990, vol 76, pp 250-256.
6. Riedel F, Hampl H, Scigalla P, et al: Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients. Kidney Int 1989;36(suppl 27):216-221.
7. Acone D, Di Maio FS, Conte D, et al: Effetto della terapia con rHuEPO sul metabolismo lipidico nel paziente in emodialisi. G Ital Nefrol 1991;8(suppl 1):469.
8. Mat O, Stolear JC, Georges B: Blood lipid profile in hemodialysis patients treated with human erythropoietin. Nephron 1992:60:236-237.
9. Viron B, Donsimoni R, Michel C, et al: Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients. Nephron 1992,60:249.
10. Kokot F, Wiecek A, Grzeszczak W, et al: Influence of erythropoietin treatment 011 endocrine abnormalities in hcmodialyzcd patients; in Baldamus CA, Koch KM. Scigalla P. Wicczorek L (eds): Erythropoietin: From Molecular Structure to Clinical Application. Contrib Nephrol. Basel. Karger. 1990, vol 76, pp 257-272.
11. Navino C, Barbè MC, Zamboni G, et al: La migliorata tolleranza glicidica dopo eritropoie-tina (EPO) negli emodializzati: Azione diretta del farmaco o aumento dell’cmoglobina? Atti del 32° Congresso Nazionale della Società Italiana di Nefrologia. Bologna 1991. Bologna. Monduzzi. 1991, pp 897-901.
12. Borissova AM, Djambazova A, Todorov K, et al: Effect of erythropoietin on the metabolic stale and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant 1993:8:93.
13. Chagnac A, Korzets A, Zevin D, et al: Erythropoietin (EPO) impairs glucose tolerance in hemodialysis patients. Nephrol Dial Transplant 1992;7:766-767.
14. Guames V, Alvarez-Buylla R: Erythrocytes and glucose homeostasis in rats. Diabetes 1989; 38:410-415.
15. Dionne KE, Colton CK, Yarmush ML: Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993;42:12-21.
16. Allegra V, Mengozzi G, D'Achille F, ct al: Glucose-induced insulin secretion in uremia: Role of anemia. Nephron 1992;62:246-247.
17. Allegra V, Mengozzi G, Vasile A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 1991:57:175-182.
18. Allegra V, Mengozzi G, Martimbianco L. et al: Glucose-induced insulin secretion in uremia: Effects of aminophyllinc infusion and glucose loads. Kidney Int 1990:38:1146-1150.
19. Allegra V, Amcndolaginc F, Mengozzi G. et al: Metabolic and hormonal assessment of patients on maintenance hemodialysis for 10 years or more and their importance in longterm survival. Nephron 1988;49:107-113.
20. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985:28:526-534.
21. Allegra V, Luisctto G, Mengozzi G, et al: Glucose-induced insulin secretion in uremia: Role of la,25(OH):-vitamin D3. Nephron 1994:68: 41-47.
22. Allegra V, Mengozzi G, Martimbianco L, et al: Glucose-induced insulin secretion in uremia: Relation with aeid-base balance and effects of bicarbonate administration. Nephron 1993:63: 43-48.
23. de Fronzo RA, Ferranini F, Koivisto V: New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med 1983:17:52-81.
24. Nissenson AR: Recombinant human erythropoietin: Impact on brain and cognitive function. exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989;9(suppl 2): 25-31.
25. Suwata J, Maeda H, Ohmori N, et al: Recombinant human erythropoietin therapy and autonomic nervous system. Nephron 1992;61:115-116.
26. Schaefer RM, Kokot F, Kuerner B, et al: Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. Int J Artif Organs 1989:12:445-449.
27. Cases A, Fscolar G, Reverter JC, et al: Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992:42:668-672.
28. Kimata H, Yoshida A, Ishioka C, et al: Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 1991:85:151-156.
29. Tsakiris D, Avramidis M, Karamitsos K, et al: Cardiopulmonary' function in haemodialysis patients before and after treatment of anaemia with erythropoietin. Kidney Int 1991:39:196.
30. Canaud B, Bouloux C, Rivorv JP, et al: Erythropoietin-induced changes in protein nutrition: Quantitative assessment by urea kinetic modeling analysis. Blood Purif 1990:8:301-308.
31. Barany P, Pcttersson E, Ahlbcrg M, et al: Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 1991:35:270-279.
32. Toigo G, Situlin R, Vasile A, et al: Effects of erythropoietin administration on nutritional state and erythrocyte metabolism in maintenance hemodialysis patients: in Guarnieri G, Panzetta G, Toigo G (eds): Metabolic and Nutritional Abnormalities in Kidney Disease. Conlrib Nephrol. Basel, Karger. 1992, vol 98, pp 79-88.
33. Kaupke CJ, Vaziri ND, Sampson JR, et al: Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients. Int J Artif Organs 1990:13:218-222.